Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 3/2014

01-03-2014 | Research Article

Identification and validation of dysregulated metabolic pathways in metastatic renal cell carcinoma

Authors: Nicole M. A. White, Daniel W. Newsted, Olena Masui, Alexander D. Romaschin, K. W. Michael Siu, George M. Yousef

Published in: Tumor Biology | Issue 3/2014

Login to get access

Abstract

Metastatic renal cell carcinoma (mRCC) is a devastating disease with a 5-year survival rate of approximately 9 % and low response to chemotherapy and radiotherapy. Targeted therapies have slightly improved patient survival, but are only effective in a small subset of patients, who eventually develop resistance. A better understanding of pathways contributing to tumor progression and metastasis will allow for the development of novel targeted therapies and accurate prognostic markers. We performed extensive bioinformatics coupled with experimental validation on proteins dysregulated in mRCC. Gene ontology analysis showed that many proteins are involved in oxidation reduction, metabolic processes, and signal transduction. Pathway analysis showed metabolic pathways are altered in mRCC including glycolysis and pyruvate metabolism, the citric acid cycle, and the pentose phosphate pathway. RT-qPCR analysis showed that genes involved in the citric acid cycle were downregulated in metastatic RCC while genes of the pentose phosphate pathway were overexpressed. Protein–protein interaction analysis showed that most of the 198 proteins altered in mRCC clustered together and many were involved in glycolysis and pyruvate metabolism. We identified 29 reported regions of chromosomal aberrations in metastatic disease that correlate with the direction of protein dysregulation in mRCC. Furthermore, 36 proteins dysregulated in mRCC are predicted to be targets of metastasis-related miRNAs. A more comprehensive understanding of the pathways dysregulated in metastasis can be useful for the development of new therapies and novel prognostic markers. Also, multileveled analyses provide a unique “snapshot” of the molecular “environment” in RCC with prognostic and therapeutic implications.
Appendix
Available only for authorised users
Literature
1.
Jonasch E, Futreal PA, Davis IJ, Bailey ST, Kim WY, Brugarolas J, et al. State of the science: an update on renal cell carcinoma. Mol Cancer Res. 2012;10:859–80.PubMedCentralPubMedCrossRef
2.
Sun M, Lughezzani G, Perrotte P, Karakiewicz PI. Treatment of metastatic renal cell carcinoma. Nat Rev Urol. 2010;7:327–38.PubMedCrossRef
3.
Escudier B, Szczylik C, Porta C, Gore M. Treatment selection in metastatic renal cell carcinoma: expert consensus. Nat Rev Clin Oncol. 2012;9:327–37.PubMedCrossRef
4.
Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295:2516–24.PubMedCrossRef
5.
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584–90.PubMedCentralPubMedCrossRef
6.
Arsanious A, Bjarnason GA, Yousef GM. From bench to bedside: current and future applications of molecular profiling in renal cell carcinoma. Mol Cancer. 2009;8:20.PubMedCentralPubMedCrossRef
7.
Girgis AH, Iakovlev VV, Beheshti B, Bayani J, Squire JA, Bui A, et al. Multi-level whole genome analysis reveals candidate biomarkers in clear cell renal cell carcinoma. Cancer Res. 2012;72:5273–84.PubMedCrossRef
8.
White NM, Yousef GM. Translating molecular signatures of renal cell carcinoma into clinical practice. J Urol. 2011;186:9–11.PubMedCrossRef
9.
10.
Kaneko N, Gotoh A, Okamura N, Matsuo EI, Terao S, Watanabe M, et al. Potential tumor markers of renal cell carcinoma: α-enolase for postoperative follow up, and galectin-1 and galectin-3 for primary detection. Int J Urol. 2013;20(5):530–5.PubMedCrossRef
11.
Siu KW, DeSouza LV, Scorilas A, Romaschin AD, Honey RJ, Stewart R, et al. Differential protein expressions in renal cell carcinoma: new biomarker discovery by mass spectrometry. J Proteome Res. 2009;8:3797–807.PubMedCrossRef
12.
Junker H, Venz S, Zimmermann U, Thiele A, Scharf C, Walther R. Stage-related alterations in renal cell carcinoma—comprehensive quantitative analysis by 2D-DIGE and protein network analysis. PLoS One. 2011;6:e21867.PubMedCentralPubMedCrossRef
13.
Craven RA, Banks RE. Understanding and managing renal cell carcinoma: can proteomic studies contribute to clinical practice? Contrib Nephrol. 2008;160:88–106.PubMedCrossRef
14.
Romaschin AD, Youssef Y, Chow TF, Siu KW, DeSouza LV, Honey RJ, et al. Exploring the pathogenesis of renal cell carcinoma: pathway and bioinformatics analysis of dysregulated genes and proteins. Biol Chem. 2009;390:125–35.PubMedCrossRef
15.
Diamandis M, White NM, Yousef GM. Personalized medicine: marking a new epoch in cancer patient management. Mol Cancer Res. 2010;8:1175–87.PubMedCrossRef
16.
Yousef GM. Personalized cancer genomics: the road map to clinical implementation. Clin Chem. 2012;58:661–3.PubMedCrossRef
17.
Masui O, White NMA, DeSouza LV, Krakovska O, Matta A, Metias S, et al. Quantitative proteomic analysis in metastatic renal cell carcinoma reveals a unique set of proteins with potential prognostic significance. Mol Cell Proteomics. 2013;12:132–44.PubMedCentralPubMedCrossRef
18.
Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res. 2012;40:D109–14.PubMedCentralPubMedCrossRef
19.
Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P, et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res. 2011;39:D561–8.PubMedCentralPubMedCrossRef
20.
Gronwald J, Storkel S, Holtgreve-Grez H, Hadaczek P, Brinkschmidt C, Jauch A, et al. Comparison of DNA gains and losses in primary renal clear cell carcinomas and metastatic sites: importance of 1q and 3p copy number changes in metastatic events. Cancer Res. 1997;57:481–7.PubMed
21.
Wullich B, Riedinger S, Brinck U, Stoeckle M, Kamradt J, Ketter R, et al. Evidence for gains at 15q and 20q in brain metastases of prostate cancer. Cancer Genet Cytogenet. 2004;154:119–23.PubMedCrossRef
22.
Sayagues JM, Abad MM, Melchor HB, Gutierrez ML, Gonzalez-Gonzalez M, Jensen E, et al. Intratumoural cytogenetic heterogeneity of sporadic colorectal carcinomas suggests several pathways to liver metastasis. J Pathol. 2010;221:308–19.PubMedCrossRef
23.
Chen Y, Liou CP, Tseng HH, Jan YJ, Li CF, Tzeng CC. Deletions of chromosome 1p and 15q are associated with aggressiveness of gastrointestinal stromal tumors. J Formos Med Assoc. 2009;108:28–37.PubMedCrossRef
24.
Poetsch M, Woenckhaus C, Dittberner T, Pambor M, Lorenz G, Herrmann FH. Significance of the small subtelomeric area of chromosome 1 (1p36.3) in the progression of malignant melanoma: FISH deletion screening with YAC DNA probes. Virchows Arch. 1999;435:105–11.PubMedCrossRef
25.
Boelens MC, Kok K, van der Vlies P, van der Vries G, Sietsma H, Timens W, et al. Genomic aberrations in squamous cell lung carcinoma related to lymph node or distant metastasis. Lung Cancer. 2009;66:372–8.PubMedCrossRef
26.
Petersen S, Aninat-Meyer M, Schluns K, Gellert K, Dietel M, Petersen I. Chromosomal alterations in the clonal evolution to the metastatic stage of squamous cell carcinomas of the lung. Br J Cancer. 2000;82:65–73.PubMedCentralPubMedCrossRef
27.
Friedrich K, Weber T, Scheithauer J, Meyer W, Haroske G, Kunze KD, et al. Chromosomal genotype in breast cancer progression: comparison of primary and secondary manifestations. Cell Oncol. 2008;30:39–50.PubMed
28.
Li X, Chen J, Lu B, Peng S, Desper R, Lai M. 8p12-23 and +20q are predictors of subtypes and metastatic pathways in colorectal cancer: construction of tree models using comparative genomic hybridization data. OMICS. 2011;15:37–47.PubMedCrossRef
29.
Bockmuhl U, You X, Pacyna-Gengelbach M, Arps H, Draf W, Petersen I. CGH pattern of esthesioneuroblastoma and their metastases. Brain Pathol. 2004;14:158–63.PubMedCrossRef
30.
Alcock HE, Stephenson TJ, Royds JA, Hammond DW. Analysis of colorectal tumor progression by microdissection and comparative genomic hybridization. Genes Chromosomes Cancer. 2003;37:369–80.PubMedCrossRef
31.
Knosel T, Petersen S, Schwabe H, Schluns K, Stein U, Schlag PM, et al. Incidence of chromosomal imbalances in advanced colorectal carcinomas and their metastases. Virchows Arch. 2002;440:187–94.PubMedCrossRef
32.
Maitra A, Molberg K, Albores-Saavedra J, Lindberg G. Loss of Dpc4 expression in colonic adenocarcinomas correlates with the presence of metastatic disease. Am J Pathol. 2000;157:1105–11.PubMedCentralPubMedCrossRef
33.
Nakamura M, Ishida E, Shimada K, Kishi M, Nakase H, Sakaki T, et al. Frequent LOH on 22q12.3 and TIMP-3 inactivation occur in the progression to secondary glioblastomas. Lab Invest. 2005;85:165–75.PubMedCrossRef
34.
Shiraishi K, Okita K, Harada T, Kusano N, Furui T, Kondoh S, et al. Comparative genomic hybridization analysis of genetic aberrations associated with development and progression of biliary tract carcinomas. Cancer. 2001;91:570–7.PubMedCrossRef
35.
Gagos S, Hopwood VL, Iliopoulos D, Kostakis A, Karayannakos P, Yatzides H, et al. Chromosomal markers associated with metastasis in two colon cancer cell lines established from the same patient. Anticancer Res. 1995;15:369–78.PubMed
36.
Goeze A, Schluns K, Wolf G, Thasler Z, Petersen S, Petersen I. Chromosomal imbalances of primary and metastatic lung adenocarcinomas. J Pathol. 2002;196:8–16.PubMedCrossRef
37.
Bockmuhl U, Schluns K, Schmidt S, Matthias S, Petersen I. Chromosomal alterations during metastasis formation of head and neck squamous cell carcinoma. Genes Chromosomes Cancer. 2002;33:29–35.PubMedCrossRef
38.
White NM, Khella HW, Grigull J, Adzovic S, Youssef YM, Honey RJ, et al. Yousef GM: miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215. Br J Cancer. 2011;105:1741–9.PubMedCentralPubMedCrossRef
39.
Khella HW, White NM, Faragalla H, Gabril M, Boazak M, Dorian D, et al. Exploring the role of miRNAs in renal cell carcinoma progression and metastasis through bioinformatic and experimental analyses. Tumour Biol. 2012;33:131–40.PubMedCrossRef
40.
Pencheva N, Tran H, Buss C, Huh D, Drobnjak M, Busam K, et al. Convergent multi-miRNA targeting of ApoE drives LRP1/LRP8-dependent melanoma metastasis and angiogenesis. Cell. 2012;151:1068–82.PubMedCentralPubMedCrossRef
41.
Chen YR, Juan HF, Huang HC, Huang HH, Lee YJ, Liao MY, et al. Quantitative proteomic and genomic profiling reveals metastasis-related protein expression patterns in gastric cancer cells. J Proteome Res. 2006;5:2727–42.PubMedCrossRef
42.
Chen YW, Chou HC, Lyu PC, Yin HS, Huang FL, Chang WS, et al. Mitochondrial proteomics analysis of tumorigenic and metastatic breast cancer markers. Funct Integr Genomics. 2011;11:225–39.PubMedCrossRef
43.
Vydra J, Selicharova I, Smutna K, Sanda M, Matouskova E, Bursikova E, et al. Two-dimensional electrophoretic comparison of metastatic and non-metastatic human breast tumors using in vitro cultured epithelial cells derived from the cancer tissues. BMC Cancer. 2008;8:107.PubMedCentralPubMedCrossRef
44.
Wu W, Tang X, Hu W, Lotan R, Hong WK, Mao L. Identification and validation of metastasis-associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry. Clin Exp Metastasis. 2002;19:319–26.PubMedCrossRef
45.
Fellenberg J, Bernd L, Delling G, Witte D, Zahlten-Hinguranage A. Prognostic significance of drug-regulated genes in high-grade osteosarcoma. Mod Pathol. 2007;20:1085–94.PubMedCrossRef
46.
Yao R, Davidson DD, Lopez-Beltran A, MacLennan GT, Montironi R, Cheng L. The S100 proteins for screening and prognostic grading of bladder cancer. Histol Histopathol. 2007;22:1025–32.PubMed
47.
Xiao MB, Jiang F, Ni WK, Chen BY, Lu CH, Li XY, et al. High expression of S100A11 in pancreatic adenocarcinoma is an unfavorable prognostic marker. Med Oncol. 2012;29:1886–91.PubMedCrossRef
48.
Ji P, Diederichs S, Wang W, Boing S, Metzger R, Schneider PM, et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 2003;22:8031–41.PubMedCrossRef
49.
Wang WS, Chen PM, Hsiao HL, Ju SY, Su Y. Overexpression of the thymosin beta-4 gene is associated with malignant progression of SW480 colon cancer cells. Oncogene. 2003;22:3297–306.PubMedCrossRef
50.
Kim NS, Kang YJ, Jo JO, Kim HY, Oh YR, Kim YO, et al. Elevated expression of thymosin beta4, vascular endothelial growth factor (VEGF), and hypoxia inducible factor (HIF)-1alpha in early-stage cervical cancers. Pathol Oncol Res. 2011;17:493–502.PubMedCrossRef
51.
Hu L, Lau SH, Tzang CH, Wen JM, Wang W, Xie D, et al. Association of Vimentin overexpression and hepatocellular carcinoma metastasis. Oncogene. 2004;23:298–302.PubMedCrossRef
52.
Hagemann T, Bozanovic T, Hooper S, Ljubic A, Slettenaar VI, Wilson JL, et al. Molecular profiling of cervical cancer progression. Br J Cancer. 2007;96:321–8.PubMedCentralPubMedCrossRef
53.
Conti A, Rodriguez GC, Chiechi A, Blazquez RM, Barbado V, Krenacs T, et al. Identification of potential biomarkers for giant cell tumor of bone using comparative proteomics analysis. Am J Pathol. 2011;178:88–97.PubMedCentralPubMedCrossRef
54.
55.
56.
Wu CA, Chao Y, Shiah SG, Lin WW. Nutrient deprivation induces the Warburg effect through ROS/AMPK-dependent activation of pyruvate dehydrogenase kinase. Biochim Biophys Acta. 1833;2013:1147–56.
57.
San MA, Ceballo S, Ruminot I, Lerchundi R, Frommer WB, Barros LF. A genetically encoded FRET lactate sensor and its use to detect the warburg effect in single cancer cells. PLoS One. 2013;8:e57712.CrossRef
58.
No authors listed (2013) AMPK can suppress tumorigenesis and the Warburg effect. Cancer Discov 3:OF15.
59.
Buppajarntham S, Junpaparp P, Kue AP (2013) Warburg effect associated with transformed lymphoplasmacytic lymphoma to diffuse large B-cell lymphoma. Am J Emerg Med 1(6):999.e5–6
60.
Poteet E, Choudhury GR, Winters A, Li W, Ryou MG, Liu R, et al. Reversing the Warburg effect as a treatment for glioblastoma. J Biol Chem. 2013;288(13):9153–64.PubMedCrossRefPubMedCentral
61.
Brizel DM, Schroeder T, Scher RL, Walenta S, Clough RW, Dewhirst MW, et al. Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001;51:349–53.PubMedCrossRef
62.
Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfor K, Rofstad EK, et al. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res. 2000;60:916–21.PubMed
63.
Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4:891–9.PubMedCrossRef
64.
Glufosfamide: beta-D-Glc-IPM, D 19575. Drugs R D 2005;6(1):49–52.
65.
Mazur L, Opydo-Chanek M, Stojak M. Glufosfamide as a new oxazaphosphorine anticancer agent. Anticancer Drugs. 2011;22:488–93.PubMedCrossRef
66.
Chiorean EG, Dragovich T, Hamm J, Langmuir VK, Kroll S, Jung DT, et al. A phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2008;61:1019–26.PubMedCrossRef
67.
Ciuleanu TE, Pavlovsky AV, Bodoky G, Garin AM, Langmuir VK, Kroll S, et al. A randomised phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. Eur J Cancer. 2009;45:1589–96.PubMedCrossRef
68.
Shimizu T, Okamoto I, Tamura K, Satoh T, Miyazaki M, Akashi Y, et al. Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D-19575 (glufosfamide) in patients with solid tumors. Cancer Chemother Pharmacol. 2010;65:243–50.PubMedCrossRef
69.
Chan DA, Sutphin PD, Nguyen P, Turcotte S, Lai EW, Banh A, Reynolds GE, Chi JT, Wu J, Solow-Cordero DE, Bonnet M, Flanagan JU, Bouley DM, Graves EE, Denny WA, Hay MP, Giaccia AJ: Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med. 2011;3:94ra70.
70.
Cao J, Cui S, Li S, Du C, Tian J, Wan S, et al. Targeted cancer therapy with a 2-deoxyglucose-based adriamycin complex. Cancer Res. 2013;73:1362–73.PubMedCrossRef
71.
Pollard PJ, Wortham NC, Tomlinson IP. The TCA cycle and tumorigenesis: the examples of fumarate hydratase and succinate dehydrogenase. Ann Med. 2003;35:632–9.PubMedCrossRef
72.
Denkert C, Budczies J, Weichert W, Wohlgemuth G, Scholz M, Kind T, et al. Metabolite profiling of human colon carcinoma—deregulation of TCA cycle and amino acid turnover. Mol Cancer. 2008;7:72.PubMedCentralPubMedCrossRef
73.
Fernie AR, Carrari F, Sweetlove LJ. Respiratory metabolism: glycolysis, the TCA cycle and mitochondrial electron transport. Curr Opin Plant Biol. 2004;7:254–61.PubMedCrossRef
74.
Jansen M, Mohapatra G, Betensky RA, Keohane C, Louis DN. Gain of chromosome arm 1q in atypical meningioma correlates with shorter progression-free survival. Neuropathol Appl Neurobiol. 2012;38:213–9.PubMedCentralPubMedCrossRef
75.
Kilday JP, Mitra B, Domerg C, Ward J, Andreiuolo F, Osteso-Ibanez T, et al. Copy number gain of 1q25 predicts poor progression-free survival for pediatric intracranial ependymomas and enables patient risk stratification: a prospective European clinical trial cohort analysis on behalf of the Children’s Cancer Leukaemia Group (CCLG), Societe Francaise d’Oncologie Pediatrique (SFOP), and International Society for Pediatric Oncology (SIOP). Clin Cancer Res. 2012;18:2001–11.PubMedCrossRef
76.
Chen M, Ye Y, Yang H, Tamboli P, Matin S, Tannir NM, et al. Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays. Int J Cancer. 2009;125:2342–8.PubMedCentralPubMedCrossRef
77.
Capurso G, Lattimore S, Crnogorac-Jurcevic T, Panzuto F, Milione M, Bhakta V, et al. Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets. Endocr Relat Cancer. 2006;13:541–58.PubMedCrossRef
78.
Kloth JN, Gorter A, Fleuren GJ, Oosting J, Uljee S, ter HN, et al. Elevated expression of SerpinA1 and SerpinA3 in HLA-positive cervical carcinoma. J Pathol. 2008;215:222–30.PubMedCrossRef
79.
Carta F, Demuro PP, Zanini C, Santona A, Castiglia D, D’Atri S, et al. Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases. Melanoma Res. 2005;15:235–44.PubMedCrossRef
80.
Shi W, Meng Z, Chen Z, Luo J, Liu L. Proteome analysis of human pancreatic cancer cell lines with highly liver metastatic potential by antibody microarray. Mol Cell Biochem. 2011;347:117–25.PubMedCrossRef
81.
An J, Sun JY, Yuan Q, Tian HY, Qiu WL, Guo W, et al. Proteomics analysis of differentially expressed metastasis-associated proteins in adenoid cystic carcinoma cell lines of human salivary gland. Oral Oncol. 2004;40:400–8.PubMedCrossRef
82.
Descotes F, Jezequel P, Spyratos F, Campion L, Grenot C, Lerebours F, et al. Identification of potential prognostic biomarkers for node-negative breast tumours by proteomic analysis: a multicentric 2004 national PHRC study. Int J Oncol. 2012;41:92–104.PubMed
83.
Zhang H, Rakha EA, Ball GR, Spiteri I, Aleskandarany M, Paish EC, et al. The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer. Breast Cancer Res Treat. 2010;121:41–51.PubMedCrossRef
84.
Kaloshi G, Mokhtari K, Carpentier C, Taillibert S, Lejeune J, Marie Y, et al. FABP7 expression in glioblastomas: relation to prognosis, invasion and EGFR status. J Neurooncol. 2007;84:245–8.PubMedCrossRef
85.
Teng Y, Ai Z, Wang Y, Wang J, Luo L. Proteomic identification of PKM2 and HSPA5 as potential biomarkers for predicting high-risk endometrial carcinoma. J Obstet Gynaecol Res. 2013;39:317–25.PubMedCrossRef
86.
Peng XC, Gong FM, Zhao YW, Zhou LX, Xie YW, Liao HL, et al. Comparative proteomic approach identifies PKM2 and cofilin-1 as potential diagnostic, prognostic and therapeutic targets for pulmonary adenocarcinoma. PLoS One. 2011;6:e27309.PubMedCentralPubMedCrossRef
87.
Satoh Y, Mori K, Kitano K, Kitayama J, Yokota H, Sasaki H, et al. Analysis for the combination expression of CK20, FABP1 and MUC2 is sensitive for the prediction of peritoneal recurrence in gastric cancer. Jpn J Clin Oncol. 2012;42:148–52.PubMedCrossRef
Metadata
Title
Identification and validation of dysregulated metabolic pathways in metastatic renal cell carcinoma
Authors
Nicole M. A. White
Daniel W. Newsted
Olena Masui
Alexander D. Romaschin
K. W. Michael Siu
George M. Yousef
Publication date
01-03-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 3/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1245-6

Other articles of this Issue 3/2014

Tumor Biology 3/2014 Go to the issue

Research Article

Quantitative assessment of the influence of common variations (rs8034191 and rs1051730) at 15q25 and lung cancer risk

Research Article

Association between glutathione S-transferase T1 null genotype and risk of lung cancer: a meta-analysis of 55 studies

Research Article

AU-binding factor 1 expression was correlated with metadherin expression and progression of hepatocellular carcinoma

Research Article

KIAA0101 mRNA overexpression in peripheral blood mononuclear cells acts as predictive marker for hepatic cancer

Research Article

Aberrant Beclin 1 expression is closely linked to carcinogenesis, differentiation, progression, and prognosis of ovarian epithelial carcinoma

Research Article

Variability of assay methods for total and free PSA after WHO standardization
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits